PCN56 - Review of Disease Burden of Lung Cancer In China’s Beijing And Shanghai

Abstract

Lung cancer has now become NO.1 disease of all cancers in both incidence and mortality in China. Since lung cancer imposes great disease and economic burden on patients in China, lots of studies have investigated national status of disease burden of lung cancer. However, few studies pay attention to disease burden of lung cancer in China’s super big cities, such as Beijing &Shanghai. Our study aims to review lung cancer’s burden in Beijing and Shanghai to inform policy making. A comprehensive literature review of disease burden of lung cancer in Beijing Shanghai was conducted. “CNKI” and “Wanfang data”, the biggest databases for Chinese journals, were searched through to Dec. 31th, 2014. In 2010, incidence and mortality of lung cancer in China are 46.08/105 and 37.00/105. DALYs (disability adjusted life years) and economic burden of lung cancer are extremely high in both Beijing and Shanghai. DALYs of lung cancer are 42219.38 and 91962.18 in Beijing and Shanghai respectively. And average hospitalization expenditures per lung cancer inpatient are ¥38595.00 and ¥50026.65, among which average drug costs per inpatient are as high as ¥18139.65(46.97%) and ¥30356.00(60.68%). Lung cancer has made Chinese patients incur great loss in both DALYs and money, which is a conspicuous reminder to policy makers to pay more attention to management of the raging disease. And early prevention and screening of lung cancer should be priorities to slow increasing speed of disease burden.